TYRA vs. VCEL, AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, and HRMY
Should you be buying Tyra Biosciences stock or one of its competitors? The main competitors of Tyra Biosciences include Vericel (VCEL), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.
Tyra Biosciences vs. Its Competitors
Tyra Biosciences (NASDAQ:TYRA) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
Tyra Biosciences currently has a consensus target price of $30.83, indicating a potential upside of 182.18%. Vericel has a consensus target price of $61.14, indicating a potential upside of 68.28%. Given Tyra Biosciences' higher probable upside, equities analysts plainly believe Tyra Biosciences is more favorable than Vericel.
84.1% of Tyra Biosciences shares are held by institutional investors. 15.2% of Tyra Biosciences shares are held by insiders. Comparatively, 5.2% of Vericel shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Vericel has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.
Tyra Biosciences has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.
In the previous week, Vericel had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 8 mentions for Vericel and 3 mentions for Tyra Biosciences. Vericel's average media sentiment score of 1.09 beat Tyra Biosciences' score of 0.66 indicating that Vericel is being referred to more favorably in the news media.
Vericel has a net margin of 1.25% compared to Tyra Biosciences' net margin of 0.00%. Vericel's return on equity of 1.09% beat Tyra Biosciences' return on equity.
Summary
Vericel beats Tyra Biosciences on 11 of the 14 factors compared between the two stocks.
Get Tyra Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tyra Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:TYRA) was last updated on 7/17/2025 by MarketBeat.com Staff
